Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

ABIOMED (ABMD) To Launch Impella CP With SmartAssist At SCAI

Published 05/20/2019, 07:36 AM
Updated 07/09/2023, 06:31 AM

ABIOMED, Inc. (NASDAQ:ABMD) recently announced that its Impella CP with SmartAssist will be commercially available at the 2019 Society for Cardiovascular Angiography & Interventions (“SCAI”) Scientific Sessions. Additionally, majority of the Impella CP heart pumps will be transitioned to SmartAssist in fiscal 2020.

This fortifies ABIOMED’s foothold in the cardiovascular devices market.

Impella CP With SmartAssist

ABIOMED’s Impella CP with SmartAssist is designed to improve patient outcomes using real-time intelligence. Notably, it received FDA approval in 2018 in the United States.

Impella CP with SmartAssist is the only mechanical circulatory support device that calculates and displays left ventricular end-diastolic pressure, mean arterial pressure and cardiac power output. It is known for greater hemodynamic support.

It is encouraging to note that Impella CP received the Japanese PMDA (Pharmaceuticals and Medical Devices Agency) approval in the recently reported fiscal fourth quarter.

Market Prospects

The Business Research Company suggests that the cardiovascular devices market is expected to reach a value of nearly $80.68 billion by 2022, at a CAGR of 5.7%. New health reforms, a growing economy and rising awareness of healthcare fuel growth.

Price Performance

We believe that positive developments such as these will boost the Zacks Rank #4 (Sell) stock, which has lost 31.3% compared with the industry’s 3.1% decline in a year’s time. The current level compares unfavorably with the S&P 500 index’s 4% rally.

Key Picks

A few better-ranked stocks in the broader medical space are DENTSPLY SIRONA (NASDAQ:XRAY) , Masimo Corporation (NASDAQ:MASI) ad CONMED Corporation (NASDAQ:CNMD) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

DENTSPLY’s long-term earnings growth rate is expected at 11.5%.

Masimo’s long-term earnings growth rate is projected at 16.1%.

CONMED’s long-term earnings growth rate is estimated at 13.3%.

This Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>



ABIOMED, Inc. (ABMD): Free Stock Analysis Report

Masimo Corporation (MASI): Free Stock Analysis Report

DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report

CONMED Corporation (CNMD): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.